Summit Therapeutics (SMMT) Cash from Investing Activities (2017 - 2026)

Summit Therapeutics (SMMT) has reported Cash from Investing Activities for 10 consecutive years, with $222.9 million the latest figure, recorded in Q2 2026.

• Quarterly Cash from Investing Activities rose 47.8% year-over-year to $222.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$262.6 million (down 191.88% YoY) and the FY2025 annual result came in at -$174.3 million, up 15.11% from the prior year.
• Cash from Investing Activities rose to $222.9 million in Q2 2026 per SMMT's latest filing, from -$238000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for SMMT reached as high as $222.9 million in Q2 2026 and fell as low as -$645.1 million in Q1 2023.
• A 5-year average of -$41.4 million and a median of -$30500.0 in 2022 frame the typical range for Cash from Investing Activities.
• The largest YoY upside for Cash from Investing Activities was 605580.0% in 2023 against a maximum downside of 178587.81% in 2023.
• Year by year, Cash from Investing Activities stood at $10000.0 in 2022, then jumped by 605580.0% to $60.6 million in 2023, then soared by 37.83% to $83.5 million in 2024, then plunged by 681.15% to -$485.2 million in 2025, then soared by 145.94% to $222.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $222.9 million, -$238000.0, and -$485.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.